Screener
Ultragenyx Pharmaceutical RARE Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration And Royalty | $156M+28.9% | $93M-9.7% | $145.79M+25.8% | $111.94M+14.4% | $121M+6.4% | |
| Non Cash Royalty | $35M+12.9% | $20M+5.3% | $37.58M+11.9% | $24.91M+8.1% | $31M+17.9% | |
| Royalty | $102M+18.6% | $47M-2.1% | $105.6M+13.3% | $64.94M+4.3% | $86M+17.5% |
FAQ
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
